PZRX Trade on Nov 28, 2017 10:44 from Aaron-Roth: Tradervue User Stock Trades.

• PhaseRx announces that the EMA Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan medicinal product designation for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (.66)

• European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), PhaseRx's second drug candidate to treat a urea cycle disorder.

• PhaseRx received Nasdaq delisting notice for common stock to be suspended on November 1 absent an appeal -- PhaseRx will appeal (0.97 +0.01)

• On September 21, 2017, PhaseRx submitted a plan of compliance to Nasdaq addressing how it intended to regain compliance with the continued listing standards by the end of the third quarter of 2017, which was subsequently supplemented on October 10 and 18, 2017. As a result of Nasdaq's rejection of the plan of compliance and initiation of delisting procedures, PhaseRx will proceed to appeal to a Nasdaq Hearing Panel. There can be no assurance that the panel will grant PhaseRx's request for continued listing.